Compare QTTB & GLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QTTB | GLO |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.2M | 230.5M |
| IPO Year | 2018 | 2006 |
| Metric | QTTB | GLO |
|---|---|---|
| Price | $8.51 | $5.19 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $39.67 | N/A |
| AVG Volume (30 Days) | ★ 322.9K | 73.9K |
| Earning Date | 11-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 136.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $53,737,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.93 | $5.22 |
| 52 Week High | $23.57 | $6.18 |
| Indicator | QTTB | GLO |
|---|---|---|
| Relative Strength Index (RSI) | 41.77 | 31.93 |
| Support Level | $8.23 | N/A |
| Resistance Level | $9.41 | $6.09 |
| Average True Range (ATR) | 0.54 | 0.17 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 20.24 | 4.00 |
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
Clough Global Opportunities Fund is a closed-end management investment company based in the United States. Its investment objective is to provide a high level of total return by investing in equity securities of companies of any market capitalization and equity-related securities, including equity swaps and call options, as well as fixed-income securities, including both corporate and sovereign debt, in both U.S. and non-U.S. markets.